Renal allografts from deceased African American donors with two apolipoprotein L1 gene (APOL1) renal-risk variants fail sooner than kidneys from donors with fewer variants. The Kidney Donor Risk Index (KDRI) was developed to evaluate organ offers by predicting allograft longevity and includes African American race as a risk factor. Substituting APOL1 genotype for race may refine the KDRI. For 622 deceased African American kidney donors, we applied a 10-fold cross-validation approach to estimate contribution of APOL1 variants to a revised KDRI. Cross-validation was repeated 10 000 times to generate distribution of effect size associated with APOL1 genotype. Average effect size was used to derive the revised KDRI weighting. Mean current-KDRI score for all donors was 1.4930 versus mean revised-KDRI score 1.2518 for 529 donors with no or one variant and 1.8527 for 93 donors with two variants. Original and revised KDRIs had comparable survival prediction errors after transplantation, but the spread in Kidney Donor Profile Index based on presence or absence of two APOL1 variants was 37 percentage points. Replacing donor race with APOL1 genotype in KDRI better defines risk associated with kidneys transplanted from deceased African American donors, substantially improves KDRI score for 85-90% of kidneys offered, and enhances the link between donor quality and recipient need.
Introduction
With the ongoing epidemic of chronic kidney disease, the need for transplantable kidneys continues to far exceed availability. In response, as part of the new kidney allocation system (KAS), the Kidney Donor Risk Index (KDRI) was developed as a tool to evaluate organ offers by predicting allograft longevity and to potentially reduce discard rates and variability in access of hard-tomatch transplant candidates while minimizing unrealized life-years and need for retransplantation. This system, implemented in the United States in December 2014, is based on application of objective metrics to define individual donor quality that can be linked to recipient need and projected outcomes (1) (2) (3) (4) (5) . In 2009, Rao and colleagues published an equation that provides the underpinnings for the KDRI (5) . The equation incorporated 10 donor characteristics and four recipient or transplantation-procedure factors that are combined to estimate of the relative risk of posttransplant failure for a kidney from a given donor (5) . Because recipient factors are not readily available at the time of an organ offer, a modified KDRI using only the donor characteristics was adopted for the KAS (6) . KDRIs of all deceased kidney donors of a calendar year are ranked numerically and then divided into percentiles ranging from 0% to 100% (best to worse) to generate a table to map a KDRI to its Kidney Donor Profile Index (KDPI). The calculated KDRI for an individual donor is divided by the median KDRI in the prior available calendar year; that value is located on the mapping table to find its KDPI.
Among donor characteristics in the KDRI equation, African American (AA) race has a hazard ratio of 1.196, indicating 20% increased risk of allograft loss. Reasons for poorer outcomes with transplantation of kidneys from AA donors, relative to non-AA donors, remain unclear (7) . Recently, our group reported that renal-risk variants (RRVs) in the donor apolipoprotein L1 gene (APOL1) are associated with outcomes of renal allografts from AA deceased donors (8) (9) (10) . Kidneys from AA deceased donors with two APOL1 RRVs were at higher risk for early allograft failure than were kidneys from AA donors with fewer than two RRVs, recipients of which had allograft survival comparable to that for kidneys from European American (EA) donors (8) (9) (10) . KDRI emerged from data incorporating race as a self-reported construct and predates description of the APOL1 effect on renal transplant outcomes. In the current study, we estimated the size of the effect of APOL1 genotype in the KDRI equation and its potential impact on KDPI-based allocation in the new KAS in the United States.
Materials and Methods

Study cohort
We retrieved all available archived DNA samples of AA deceased donors whose kidneys were recovered and/or transplanted at three busy kidneytransplant programs with sizable populations of AA donors (Wake Forest University, Emory University, and University of Alabama at Birmingham) and the Deterioration of Kidney Allograft Function Genomics study that received samples from nine organ procurement organizations (10) . A total of 1153 deceased donor kidney transplantations were performed at 113 centers. The cohort includes 1149 recipients of kidneys from 622 deceased AA donors (529 with no or one APOL1 RRV [979 transplants]; 93 with two RRVs [170 transplants]). Four recipients were excluded because of missing data for serum creatinine.
APOL1 genotyping
Genotyping was done with a custom array designed at the Wake Forest School of Medicine to detect two single-nucleotide polymorphisms for the APOL1 G1 RRV (rs73885319; rs60910145) and an insertion/deletion for the G2 RRV (rs143830837) (10) . Genotyping of 15 blind duplicates had a concordance rate of 100%, and genotyping efficiency for the three variants comprising APOL1 G1 and G2 variants exceeded 99% for the 1149 transplantations.
Clinical outcomes
Outcomes of transplantation were determined by using United Network of Organ Sharing identification numbers to link to data in the Scientific Registry of Transplant Recipients (SRTR) that include data on all donors, waitlisted candidates, and transplant recipients in the United States, as Effects of APOL1 after adjusting for effects of donor race/ ethnicity
We randomly selected 4000 EA donors from the SRTR database and assigned them zero RRVs because APOL1 risk variants are virtually absent in this population (11, 12) . A model was fitted that included APOL1 and the 10 covariates in the current KDRI equation (including race/ethnicity). The likelihood ratio test was computed to compare the full model, which included APOL1 as a covariate, to the reduced model that did not include APOL1. For comparison, a similar test was performed to evaluate the contribution of race/ethnicity in models that already contained the APOL1 genotypes as a covariate. Random selection of EA donors was repeated 10 000 times to generate the distribution of these tests, each time taking a different random sample of 4000 EA donors.
Estimation of KDRI coefficient b for APOL1 genotype
We adopted a 10-fold cross-validation approach: nine-tenths of available observations were used to estimate a KDRI coefficient b for the APOL1 two-RRV genotype in a Cox proportional hazards regression. This estimated parameter was combined with published KDRI b components for the remaining nine donor characteristics to compute the modified KDRI. This result was used to test for association with survival outcome in the remaining one-tenth of the sample. The split-sample approach for estimating and validating the revised KDRI was repeated 10 000 times to generate the sampling distributions of the estimated parameter associated with APOL1 genotype and the estimated c-index, the probability of concordance between the predicted and observed survival. The mean of the coefficients associated with APOL1 was used for all comparisons with the original KDRI.
Calculation of KDRI
Parameter estimates associated with the 10 donor characteristics were determined in 69 440 adult first-time recipients of deceased donor kidneys in the United States from 1995 to 2005 (5). KDRI parameter estimates for age and serum creatinine were provided at specific knots (18 and 50 years for age, 1.5 mg/dL for serum creatinine); age, height, and weight were centered at 40 years, 170 cm, and 80 kg, respectively, to improve the fit of the model (13) . KDRI was calculated as the exponent of the fitted (predicted) score, KDRI = exp (Xb), in which X represents the vector of observations for the 10 variables and b is the vector of parameter estimates. We compared the current KDRI equation with our proposed revision: in the latter, APOL1 is coded as a binary variable under a recessive mode of inheritance; AA donors with two APOL1 RRVs are coded as 1, and donors with fewer RRVs are coded as 0. This coding implies that the parameter estimate for donors with no or one RRV is 0, leading to renal allograft survival rates equivalent to those for kidneys from EA donors (10) .
Assessment of KDRI to predict clinical outcomes
Efforts to evaluate the KDRI's capacity to associate donor characteristics with kidney allograft outcomes can be seen as independent efforts to validate the index; however, the number of kidney transplants from AA deceased donors with APOL1 genotype data is limited, with virtually no independent validation data set. Consequently, we opted for a splitsample approach; a fraction of the sample was used to determine overall contribution of APOL1 (i.e. xb component) in a model that included the other donor characteristics as covariates.
Discrimination and calibration measures, including overall and timedependent estimates of c-index, specificity, and sensitivity, and confidence intervals, were obtained for the current and revised KDRIs under the Cox proportional hazards model for time-to-allograft failure and competing-risk model that treated death with functional allograft as a competing risk. Overall c-index and predictive ability of both KDRIs were evaluated using bootstrap-based internal calibration and validation approaches (14) . These approaches were implemented in the R package regression modeling strategies ("rms") (15) . Time-dependent measures, including area under the receiver operating characteristic (ROC) curve or c-index, true-positive rate, false-positive rate, positive predictive value, and negative predictive value, were obtained for 1, 3, and 5 years after transplantation using a cutoff value of 1.2218 that corresponded to the median KDRI in 2014. There are several statistical approaches for estimating these parameters. Key differences among them include the manner in which censored observations are treated, the ability to derive a closed-form equation for estimating standard error associated for the estimates, and the range of models that could be considered. Few of these approaches, for example, accommodate competing-risk and correlated survival outcomes, as when two recipients receive a kidney from one donor. Estimates for prognostic accuracy of the current and revised KDRIs were calculated under the inverse probability weighting approach and under the Cox proportional odds model (16) . We derived predictive accuracy estimates under a competing-risk model (17) . This approach was implemented in R (http://CRAN.R-project.org/package=timeROC). Estimates were generated under two alternative definitions of event of interest. Area under the curve (AUC) 1 refers to area under the ROC curve relative to a "main event." Participants who experienced this event were compared with those who were event-free, namely, participants who were alive with a functional allograft before or at the time-point of interest. AUC 2 focuses on each specific type of event; participants with the event of interest are contrasted with those who did not have the event and were at risk before or at the time-point of interest.
Determination of KDPI
We divided KDRIs calculated using the current KDRI equation and the equation with APOL1 genotype instead of race by 1.2218 (median KDRI [scaling factor] of 2014) to generate KDRIs_Median. KDPI was determined by finding the KDPI assigned to the KDRI_Median in the 2014 KDRI-to-KDPI mapping table.
Results
Relative impacts of APOL1 and race on KDRI To determine relative effects of donor APOL1 genotype versus race/ethnicity on allograft survival, a model containing APOL1 genotype (two vs. no or one RRV) and ethnicity was fitted. This model contained all other covariates and was compared with a similar model that was restricted to only ethnicity. Over the 10 000 iterations, the mean chi-square statistic for this test was 4 .88 for models that tested for the significance of APOL1 when it was added last compared with 2.87 when race/ ethnicity was added last (p-values of 0.03 and 0.09, respectively). Consequently, the effect of race was no longer significant once APOL1 genotype was included in the model. In this repeated sampling experiment, effect of APOL1 was statistically significant in 99.9% of the random samples in contrast to only 24.8% for race/ ethnicity in models that also contained APOL1 genotype.
Estimation and significance of KDRI coefficient b for APOL1 two-RRV genotype Table 1 shows distributions of the nine characteristics used as donor factors in calculating KDRI between the two groups of donors based on APOL1 genotype. The groups differed only in frequency of history of diabetes (less common in donors with two APOL1 RRVs).
The observed c-index with the currently formulated KDRI tested with full data was 0.608, matching a previously published estimate (13) . Distribution of observed APOL1 genotype-revised KDRI c-indexes ranged from 0.50 to 0.90. The observed mean was 0.621, and the median was 0.618 ( Figure 1 ). APOL1-revised KDRI c-index was higher than the observed c-index for the currently formulated KDRI in 57% of 10 000 replications, indicating that the revised KDRI has at least equivalent predictive ability for transplant outcomes. Distribution of KDRI coefficient b for the APOL1 two-RRV genotype had a similar shape, with a mean of 0.411 (standard deviation [SD] 0.18) and a median of 0.413 ( Figure 1 ). We used the mean value to calculate revised KDRI scores.
APOL1-based revision of KDRI improved the score for the 85% of AA donors who possessed no or one RRV (median 1.1633 vs. 1.3913 with the current equation). For two AA donors with identical characteristics except for APOL1 genotype, two APOL1 RRVs conferred a hazard ratio that averaged 1.51 times that associated with no or one RRV (KDRI coefficient b 0.411 vs. 0.000) ( Table 2 ). Among donors with no or one APOL1 RRV, distribution of revised KDRIs had a mean of 1.2518 (SD 0.4237) and a median of 1.1633 compared with a mean of 1.8527 (SD 0.5609) and a median of 1.8154 among donors with two APOL1 RRVs. The difference between revised KDRIs was significant (p < 0.001). Table 3 compares prognostic ability of KDRIs at 1, 3, and 5 years after transplantation using a cutoff value of 1.2218 corresponding to the median KDRI in 2014. Both KDRI equations had similar performance for c-indexes and positive and negative predicted values. Estimated true-positive rates did not significantly differ. The revised KDRI had a significantly lower false-positive rate at all postengraftment time points. The current and revised KDRI equations had similar prediction errors (Nagelkerke r 2 , mean prediction error, and integrated Brier scores [IBS]) ( Table 4) . The "rms" package was used to estimate r 2 and prediction errors. IBS was estimated using a prediction error curve (18) . These estimates were generated with a bootstrapping approach. The predictive power of the KDRI equations did not differ. Table 5 presents the estimated discriminatory measures for a competing-risk model that treats death with functional allograft as competing with allograft failure. The pattern is similar to results with the model that treats death with functional allograft as a censored observation. The KDRIs had comparable performance with overlapping confidence intervals, with the revised equation providing slightly higher (better) point estimates in most cases. Point estimates of the c-indexes for death were all lower than observed c-indexes for allograft failure, independent of time-point considered and version of KDRI equation, consistent with our previous work indicating that APOL1 genotype is a better predictor of allograft failure than recipient death (9,10). *The 95% confidence intervals for the results for the current KDRI and the revised KDRI at that interval after transplantation did not overlap.
Prognostic capacity of KDRI
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Effect of APOL1 genotype on KDPI
donors were compared: an EA donor, an AA donor with no APOL1 RRVs, an AA donor with one APOL1 RRV, and an AA donor with two APOL1 RRVs. Using the current KDRI, the three AA donors were assigned identical race risk, a coefficient b of 0.179. In the revised KDRI equation using APOL1 genotype, AA donors with no or one APOL1 RRV received no adverse weighting for the characteristic because survival of such kidney was equivalent to that of kidneys from EA donors. who do not carry an APOL1 RRV (10). Example 1 showed that replacement of race by APOL1 genotype for AA donors with no or one RRV reduced a KDPI of 86% to 71%, indicating kidneys subject to standard allocation. Example 2 showed that the revised KDRI equation for an AA donor with two RRVs increased the KDPI to the 85% threshold for consideration for expanded-criteria-donor allocation; however, for AA donors with no or one RRV, the KDPI decreased to 46%. Example 3 showed that the use of APOL1 genotype for an AA donor with no or one RRV and a current KDPI of 30% reduced KDPI to 13%, within a range suitable for the best candidates. Example 4 showed that using the revised KDRI formula widely separates AA donors with KDPI 18% using the current KDRI equation from those with an outstanding KDPI of 4% (no or one RRV) or a midrange KDPI of 42% (two RRVs). In each of these scenarios, the use of APOL1 genotype would dramatically affect recipient selection.
Discussion
It has long been known that kidneys donated by AA deceased donors fare worse after transplantation than kidneys from non-AA donors, regardless of the race of the recipient (19) (20) (21) (22) . Epidemiologic data are consistent enough that donor race, despite its weakness as a biological construct, was incorporated into the KDRI equation (5, 6 ). An important and growing body of evidence (17) . AUC 1 refers to the estimated c-index, assuming controls are free of either event (participants who are alive with a functioning allograft) before the time point of interest. AUC 2 focuses on each specific type of failure; therefore, an AUC 2 estimate for allograft failure (e.g., at 3 years) assumes that controls are alive at 3 years after transplantation. AUC, area under the curve.
now indicates that poor outcomes attributable to race may better associate with donor APOL1 genotype. Five years after engraftment, kidneys from AA deceased donors with two APOL1 RRVs were more than twice as likely to have failed than those from donors with fewer RRVs (9,10). Renal histology in most failed allografts from donors with two APOL1 RRVs displayed APOL1-associated lesions (8) . In contrast, for kidneys from AA deceased donors with no or one APOL1 RRV, long-term outcomes appeared to be equivalent to those with kidneys from EA deceased donors (8) (9) (10) . The KDRI equation was developed before the APOL1 effect in deceased-donor kidney transplantation was identified; in the face of emerging evidence in this regard and the vagaries associated with inclusion of a variable termed "race," reassessment of current equations is indicated (5, 6) . We propose inclusion of APOL1 genotyping in KDPI-based allocation as a significant advance in both objectivity and predictive utility.
In the current analysis, the effect of two APOL1 RRVs on allograft survival was substantial. The calculated KDRI coefficient b 0.411 and corresponding hazard ratio 1.508 contrast with values for AA race of 0.1790 and 1.196 using the current KDRI equation, and the weighting for two APOL1 RRVs exceeds that of the other nine donor characteristics (5,6). The C statistic in our models ranged from 0.58 to 0.65, numbers that coincide with the predictive value of the current KDRI equation. Although the comparative performance of the revised KDRI is modest, more kidneys from AA donors would likely be available for transplantation. In the interval 2011-2015, kidneys for transplantation have been recovered from 5752 AA deceased donors (23) . A KDRI calculated with the substitution of race by APOL1 genotype places a higher penalty on renal allografts from the 13% of AA deceased donors with two APOL1 RRVs while removing the unnecessary penalty applied to the AA deceased donors who carry fewer RRVs. This change means that as many as 10 000 kidneys from about 5004 donors over the past 5 years likely would have been offered to patients with significantly more favorable prognoses and thus better utilized. Notably, this change in the formula did not reduce the predictive and discriminatory powers of the KDRI. Likelihood ratio tests comparing models that included APOL1 genotype and race to models that had only race/ethnicity as a covariate revealed that APOL1 genotypes consistently and significantly affected allograft survival after deceased-donor kidney transplantation. In this data set, the effect of race in conjunction with APOL1 was less clear, with only one of four models showing a significant effect, suggesting that APOL1 may account for the preponderance of what has been termed the "race effect" associated with AA donors. More data are needed to fully estimate the residual contribution of race beyond APOL1 genotype.
There are potential benefits in revising the current KDRI equation, as suggested. As implied, using donor APOL1 genotype rather than race is likely to improve the allocation of better quality kidneys to patients projected to have longer posttransplant survival (estimated posttransplant survival [EPTS]), enhancing a major stated goal of the KAS. For kidneys from AA deceased donors currently assessed as being of sufficiently poor quality (KDPI ≥85%) to merit allocation to patients with limited EPTS or consideration for discard, substitution of APOL1 genotype for race in the KDRI equation would Although our work indicates no adverse impact on allograft survival of kidneys with no or one APOL1 RRV, a larger experience might (or might not) identify an effect on outcome. The data we used to estimate the APOL1 effect lacked prospective follow-up and some potentially important clinical data, including histology of failed allografts, dosing and exposure to immunosuppressive medications, frequency and type of viral infections, presence of donor-specific anti-HLA antibodies, and occurrence of acute rejection or delayed allograft function (10) . However, data used to derive KDRI also lack this granularity. Furthermore, prior studies have not obtained genotype data for APOL1 for recipients or other loci for donors; these data are needed to robustly test whether renal allograft survival is the consequence of donor APOL1 genotype or mere association. Again, however, two parameters already incorporated in KDRI (race and age) also do not link cause and effect.
There may be potential practical drawbacks to replacing race in KDRI with APOL1 genotype, although their merit may be diminishing. As noted earlier, evidence supporting the impact of two APOL1 RRVs on kidney disease and allograft survival is expanding rapidly. The statistical effect documented in our work is strong and defines only potential benefit on allocation and allograft survival, without indication of adverse impact on either end-point. Clinical availability of APOL1 genotyping is also growing and is now a standard offering from many commercial laboratories. The costs of APOL1 genotyping are declining and are relatively modest, especially when considering the likelihood of an increased pool of donor kidneys and the potential for improved allograft survival by better matching of donors and recipients. Finally, even our own concern about tight turnaround constraints associated with organ recovery from deceased donors is increasingly alleviated with broad incorporation of polymerase chain reaction testing for viral infections, now standard as part of the U.S. Public Health Service guidelines across the country. Adding APOL1 genotyping would seem a minor hurdle. Despite these trends, we recognize the limitations of our efforts and the need for additional work and modeling prior to incorporation of APOL1 status into the organ-allocation process (26, 27) . By pointing out both the scope and the potential benefit of such a change, perhaps these other efforts can be hastened.
In conclusion, the effect of adjusting the KDRI equation by using APOL1 genotype instead of race is substantial and likely to be beneficial. Revision of the KDRI formula would favorably affect the stated goals of the new KAS and enhance the precision of organ allocation, with the potential to improve overall allograft survival. We believe that confirmation of our findings and their subsequent incorporation into national policy represent significant advances in this era of organ shortage that would benefit not only minority candidates but all stakeholders.
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